The potential of ciRS-7 for predicting onset and prognosis of cervical cancer
- Free access
Abstract:
Considering the potency of circRNAs in manifesting neoplastic progression, we attempted to explore the feasibility of applying ciRS-7 for diagnosis and prognosis estimation of cervical cancer (CC). Here 352 CC patients, 204 cervical intraepithelial neoplasia (CIN) patients and 227 healthy controls were recruited. The Kaplan-Meier survival curves were fitted to estimate associations of ciRS-7 expression with CC prognosis, and we also adopted receiver operating characteristic (ROC) curves to assess the diagnostic performance of ciRS-7 for CC. Meanwhile, endometrial stromal cell line (ESC) and 4 human CC cell lines (i.e. Hela, CaSki, C33A and SiHa) were also gathered. After transfection of pcDNA3.1-ciRS-7, impacts of overexpressed ciRS-7 on proliferation, apoptosis, invasion and migration of CC cells were assessed through performing colony formation assay, flow cytometry, transwell assay and wound healing assay. The results demonstrated that CC patients that highly expressed ciRS-7 were associated with high odds of large tumor size, advanced FIGO stage, deep invasion, metastatic lymph nodes and HPV infection (p<0.05). Furthermore, ciRS-7 excelled in differentiating CC patients from healthy controls and CIN patients than CEA and CA125 (p<0.05), and ciRS-7 combined with CA125 and CEA generated an optimum efficacy in diagnosing CC patients and CIN patients from healthy controls (p<0.05). Concerning in vitro experiments, elevating ciRS-7 expression significantly intensified proliferation and epithelial-mesenchymal transition (EMT) of CC cells (p<0.05), and also markedly suppressed apoptosis of the cells (p<0.05). In conclusion, ciRS-7 possessed great potential in clinical diagnosis of CC, given its involvement in modulating the activity of CC cells.
Received date: 04/15/2019
Accepted date: 07/24/2019
Ahead of print publish date: 12/23/2019
Issue: 2/2020
Volume: 67
Pages: 312 — 322
Keywords: ciRS-7, cervical cancer, CEA, CA-125, combined diagnosis, cell proliferation, epithelial-mesenchymal transition
DOI: 10.4149/neo_2019_190415N334